Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2019 Jun 25;57(7):e00060-19.
doi: 10.1128/JCM.00060-19. Print 2019 Jul.

Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras

Affiliations
Comparative Study

Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras

Kai-Henrik Peiffer et al. J Clin Microbiol. .

Abstract

Besides seven major hepatitis C virus (HCV) genotypes (GT), a number of intergenotypic recombinant strains have been described. These so-called chimeras combine genetic characteristics of different HCV genotypes. However, correct genotype classification is important, as choice and duration of direct-acting antiviral (DAA) treatment is mainly based on the viral genotype. Therefore, misclassification of chimeras might lead to suboptimal treatment of patients infected with these strains. For example, 2k/1b chimeras are typically described as HCV genotype 2 strains by commercially available hybridization assays, but real-time PCR-based tests recognizing another HCV region might be more suitable for correct chimera detection. In this study, the analytic capacity of the hybridization-assay Versant HCV Genotype 2.0 (LiPA 2.0) and the real-time PCR-based-assays cobas HCV GT and Abbott RealTime HCV Genotype II were tested in a selected cohort of 230 patients infected with HCV genotype 1 (n = 53) and 2 (n = 177) and 48 patients infected with HCV 2/1 chimeric strains. While the Versant HCV Genotype 2.0 (LiPA 2.0) assay failed to identify chimeras in all of the patients (48/48, 100%), cobas HCV GT and Abbott HCV Genotype II assays identified chimeras correctly in 90% (43/48) and 65% (31/48) of the cases, respectively. In conclusion, while the hybridization-based Versant HCV Genotype 2.0 (LiPA 2.0) assay seems to be unsuitable for detection of HCV 2/1 chimeras, use of the real-time PCR-based assays cobas HCV GT and Abbott RealTime HCV Genotype II led to a higher rate of chimera detection.

Keywords: 2k/1b; assay; chimera; hepatitis C virus; recombinant.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Percentage of chimeras identified by the hybridization-based assay Versant HCV Genotype 2.0 and the real-time PCR-based assays cobas HCV GT and Abbott RealTime HCV Genotype II.
FIG 2
FIG 2
(a) Overview of genotype and subtype determination by the hybridization-based assay Versant HCV Genotype 2.0 and the real-time PCR-based assay cobas HCV GT in comparison to that by population-based sequencing. If genotype or subtype were consistent with sequencing results, calls were termed consistent; otherwise, the subtype was refined by the sequencing analysis. (b and c) Detailed subtype determination by the hybridization-based assay Versant HCV Genotype 2.0 (b) and by the real-time PCR-based-assay cobas HCV GT (c) in comparison to that by population-based sequencing. If subtype was consistent with sequencing results, calls were termed consistent; otherwise, the subtype was refined by the sequencing analysis.
FIG 3
FIG 3
Schematic representation of viral recombination in HCV 2k/1b and targets for genotype typing/subtyping by the assays Versant HCV Genotype 2.0 (LiPA 2.0), cobas HCV GT, and Abbott RealTime HCV Genotype II. UTR, untranslated region; E, envelope protein; NS, nonstructural protein; gt, genotype.

References

    1. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59:318–327. doi:10.1002/hep.26744. - DOI - PMC - PubMed
    1. Hedskog C, Doehle B, Chodavarapu K, Gontcharova V, Crespo Garcia J, De Knegt R, Drenth JP, McHutchison JG, Brainard D, Stamm LM, Miller MD, Svarovskaia E, Mo H. 2015. Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. Hepatology 61:471–480. doi:10.1002/hep.27361. - DOI - PubMed
    1. Kalinina O, Norder H, Mukomolov S, Magnius LO. 2002. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol 76:4034–4043. doi:10.1128/JVI.76.8.4034-4043.2002. - DOI - PMC - PubMed
    1. Susser S, Dietz J, Schlevogt B, Zuckerman E, Barak M, Piazzolla V, Howe A, Hinrichsen H, Passmann S, Daniel R, Cornberg M, Mangia A, Zeuzem S, Sarrazin C. 2017. Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras. J Hepatol 67:680–686. doi:10.1016/j.jhep.2017.05.027. - DOI - PubMed
    1. De Keukeleire S, Descheemaeker P, Reynders M. 2015. Potential risk of misclassification HCV 2k/1b strains as HCV 2a/2c using VERSANT HCV Genotype 2.0 assay. Diagn Microbiol Infect Dis 82:201–202. doi:10.1016/j.diagmicrobio.2015.04.001. - DOI - PubMed

Publication types